Indian Pharmacopoeia 2014 ★

For the first time, 19 new radiopharmaceutical monographs and one general chapter were included to regulate diagnostic and therapeutic nuclear medicines.

These addenda made IP 2014 a living document, relevant for nearly four years until IP 2018 was launched. indian pharmacopoeia 2014

To appreciate IP 2014, it helps to see where it sits in the timeline: For the first time, 19 new radiopharmaceutical monographs

IP 2014 did not merely list tests and limits; it raised the bar. It forced manufacturers to discard obsolete methods, adopt global best practices, and think critically about impurity control. For regulators, it provided teeth. For patients, it offered assurance that their medicine meets a standard backed by science and law. For the first time